Tema Etfs LLC Decreases Stock Holdings in Insulet Corporation $PODD

Key Points

• Tema Etfs LLC has reduced its holdings in Insulet Corporation by 23.2%, selling 1,251 shares and leaving it with 4,134 shares valued at approximately $1,086,000 as of the latest SEC filing.
• Insulet's recent earnings surpassed expectations, reporting $1.17 earnings per share for the quarter, significantly above the consensus estimate of $0.92, with a revenue increase of 32.9% compared to the previous year.
• Research firms have recently upgraded Insulet's stock ratings, with Barclays and Royal Bank of Canada increasing their target prices to as high as $350.00, reflecting a positive outlook for the company.

Tema Etfs LLC reduced its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 23.2% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 4,134 shares of the medical instruments supplier's stock after selling 1,251 shares during the quarter. Tema Etfs LLC's holdings in Insulet were worth $1,086,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its position in shares of Insulet by 55.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,229 shares of the medical instruments supplier's stock valued at $1,376,000 after purchasing an additional 1,867 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Insulet by 85.1% in the 1st quarter. Farther Finance Advisors LLC now owns 896 shares of the medical instruments supplier's stock valued at $236,000 after purchasing an additional 412 shares during the last quarter. QRG Capital Management Inc. raised its position in shares of Insulet by 75.6% in the 1st quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier's stock valued at $533,000 after purchasing an additional 874 shares during the last quarter. Exchange Traded Concepts LLC raised its position in shares of Insulet by 225.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier's stock valued at $408,000 after purchasing an additional 1,075 shares during the last quarter. Finally, State of Alaska Department of Revenue raised its position in shares of Insulet by 2.6% in the 1st quarter. State of Alaska Department of Revenue now owns 8,212 shares of the medical instruments supplier's stock valued at $2,156,000 after purchasing an additional 210 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wells Fargo & Company increased their price objective on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research report on Friday, August 8th. Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a report on Thursday, August 7th. The Goldman Sachs Group began coverage on shares of Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 price target on the stock. Truist Financial began coverage on shares of Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price target on the stock. Finally, Citigroup reiterated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $332.71.

Insulet Stock Performance

Shares of NASDAQ PODD traded up $2.28 during midday trading on Monday, reaching $339.88. 515,158 shares of the stock were exchanged, compared to its average volume of 702,791. The firm has a market cap of $23.93 billion, a price-to-earnings ratio of 103.31, a PEG ratio of 2.85 and a beta of 1.36. Insulet Corporation has a twelve month low of $199.68 and a twelve month high of $341.14. The firm has a 50-day simple moving average of $304.04 and a two-hundred day simple moving average of $287.71. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same quarter last year, the firm posted $0.55 EPS. The business's revenue was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.